anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention belongs to the technical field of biology, and relates to a new target for inhibiting bladder cancer metastasis and application thereof. The invention takes bladder cancer T24T and UMUC3 cells as models, and the transfer characteristic of the bladder cancer cells can be reduced in vitro and in vivo by inhibiting miR-3648 expression. Therefore, the miR-3648 expression inhibitor can inhibit bladder cancer metastasis. The method for detecting that miR-3648 expression in most clinical high-grade invasive bladder cancer tissues is in a significant up-regulation trend by using a real-time fluorescent quantitative PCR (polymerase chain reaction) technology, a bioinformatics analysis TCGA (tcGA) database and other methods. As can be seen, the expression of miR-3648 is closely related to high-grade invasive bladder cancer through detection. The invention is expected to provide a new target and corresponding measures for inhibiting bladder cancer metastasis.
An additional aim was added to this project, examining the effect of a telephone intervention on eye care adherence and comparing the efficacy of the intervention to usual care and automated telephone screenings.

Glaucoma is a group of chronic, neurodegenerative diseases of the optic nerve, which leads to an increase in intraocular pressure, gradual changes in the visual field (VF), and progressive vision loss. Glaucomatous vision loss is preventable with proper eye care, including adherence to follow-up appointments and medications. Interventions that improve appointment adherence have the potential to prevent more severe glaucomatous disease. The primary purpose of this study is to determine the efficacy of a multifaceted intervention system, which includes a customized letter and personal telephone outreach, in improving appointment adherence in patients with glaucoma. In order to improve strategies to reduce the rate of appointment non-adherence, shared characteristics of adherent versus non-adherent patients with glaucoma will be identified and compared to patient characteristics in the previous literature. A secondary goal of this study is to analyze the cost-effectiveness of this multifaceted intervention on appointment adherence in patients with glaucoma.
OBJECTIVES: This study evaluates the impact of equol, a metabolite of soy isoflavone, on bladder dysfunction in rats with bladder outlet obstruction (BOO). In addition, we investigate its potential as a neuroprotective agent for the obstructed bladder and discuss its applicability in managing overactive bladder (OAB).
METHODS: Eighteen male Sprague-Dawley rats were divided into three groups (six rats per group) during the rearing period. The Sham and C-BOO groups received an equol-free diet, while the E-BOO group received equol supplementation (0.25 g/kg). At 8 weeks old, rats underwent BOO surgery, followed by continuous cystometry after 4 weeks of rearing. The urinary oxidative stress markers (8-hydroxy-2'-deoxyguanosine and malondialdehyde) were measured, and the bladder histology was analyzed using hematoxylin-eosin, Masson's trichrome, and immunohistochemical staining (neurofilament heavy chain for myelinated nerves, peripherin for unmyelinated nerves, and malondialdehyde).
RESULTS: Equol reduced BOO-induced smooth muscle layer fibrosis, significantly prolonged the micturition interval (C-BOO: 193 s, E-BOO: 438 s) and increased the micturition volume (C-BOO: 0.54 mL, E-BOO: 1.02 mL) compared to the C-BOO group. Equol inhibited the increase in urinary and bladder tissue malondialdehyde levels. While the C-BOO group exhibited reduced peripherin alone positive nerve fibers within the smooth muscle layer, equol effectively attenuated this decline.
CONCLUSIONS: Equol reduces lipid peroxidation and smooth muscle layer fibrosis in the bladder and exhibited neuroprotective effects on bladder nerves (peripheral nerves) and prevented the development of bladder dysfunction associated with BOO in rats. Consumption of equol is promising for the prevention of OAB associated with BOO.
1. Use of Ginkgo biloba extract, comprising terpene of less than 3% w/w or flavone heterosides greater than 24% w/w of dry matter for the preparation of a composition with immunomodulatory activity via the topical route. 2. Use of claim 1 characterized in that the composition is intended to prevent or to treat immunodependent skin reactions. 3. Use according to either of claims 1 and 2, characterized in that an extract obtained from Ginkgo biloba leaves. 4. Use according to one of claims 1 to 3, characterized in that the composition is intended for the treatment or for the preparation of intolerance and/or allergy reactions of the skin and of the mucous membranes. 5. Use according to one of claims 1 to 4, characterized in that the composition is intended for the treatment or prevention of a condition chosen from the group consisting of: atopy, vitiligo, psoriasis, erythema multiforme, neurodermatitis, xeroderma, urticaria, pemphigus, rosacea, lupus erythematosus, dermatitis, benign aestival photodermatitis, eczema and AIDS-related dermatological manifestations. 6. Use according to claim 5, characterized in that the Ginkgo biloba extract is present in the composition at a concentration of between 0.0001 and 10% w/w 7. Use according to one of claims 3 to 6, characterized in that the Ginkgo extract is present in the composition at a concentration of between 0.01% and 2% w/w. 8. Method for the cosmetic treatment of hyperreactive skins, characterized in that the composition is applied on the skin via the topical route, the composition comprising extraction from Ginkgo biloba and terpene of less than 3% w/w or flavone heterosides greater than 24% w/w of dry matter. 9. Method according to claim 10, characterized in that a dermocosmetic composition containing a Ginkgo biloba extract in combination with dermatologically acceptable excipients is applied via the topical route.
The invention relates to medicine, more specifically hepatology, and can be used for treating chronic viral hepatitis C, the causative agent of which can be of any genotype. The technical result of the proposed method is a reduction in the aggressiveness of antiviral therapy together with an increase in stable positive therapeutic results. In the claimed method for treating chronic viral hepatitis C, which involves administering short-lived interferon-alpha (IFN) and the nucleoside analogue Ribamidil to the patient, an average weekly starting dose of interferons in a range of 10.5-21.0 million SU is determined on the basis of the patient's own interferon-alpha level, and interferon-alpha is administered with an at least twofold gradual increase in the average weekly dose of interferons to a value of 21.0-84 million SU. Throughout the entire IFN administration period, additional antiviral drugs, namely an interferon inducer, are administered to the patient, as well as an amantadine group preparation or a glycyrrhizic acid preparation. At the same time, a concomitant treatment is carried out which involves the administration of T cell immunity stimulators and preparations for combating side effects. The presence of viral ribonucleic acid (RNA) in the patient's blood is periodically monitored: a daily dose of 800-1200 mg of Ribamidil is administered starting from the third month from the commencement of treatment if ribonucleic acid (RNA) is present in the patient's blood, or starting from the tenth month if no RNA is present. Treatment is continued until at least a twelve month period of aviremia has passed.
Conventional full-awake extubation will be performed based on the routine practice of our institution. At the end of surgery, sevoflurane will be stopped, and the attending anesthesiologist will lead the emergence process, allowing the patient to breathe spontaneously and providing intermittent manual assistance if necessary. Extubation will be performed when the patient meets the following criteria: obeys commands such as eye-opening or hand-grip, tidal volume \> 5 ml/kg, end-tidal carbon dioxide \< 45 mmHg, spontaneous respiratory rate 10 to 20 breaths/min.
For the evaluation of altered osteogenesis by bone scintigraphy each research subject will serve as his/her own control, and undergo imaging using both generator- and cyclotron-produced 99mTc. Each study will be performed on a separate day, with flexibility to schedule either study first.
1 A vaccine composition, containing capsular polysaccharide antigen of type b Haemophilus influenza, or high molecular weight polyribosylribitol phosphate, coupled to the tetanus toxoid and an aluminium-based adjuvant, wherein the aluminium-based adjuvant has, a zero point of charge of less than about 7.2 2. Vaccine composition of Claim 1, wherein the aluminium-based adjuvant is aluminum hydroxides, to which compounds are added, forming anions. 3. Vaccine composition of Claim 1, wherein said compounds are phosphates and citrates. 4. Vaccine composition of any preceding Claim wherein the aluminium-based adjuvant is aluminum phosphates. 5. Vaccine composition of any preceding Claim wherein the aluminium-based adjuvant is potassium and aluminum sulfates. 6. Vaccine composition of any preceding Claim wherein further containing one or more antigens representing diptheria, tetanus, whooping cough antigen or antigen of hepatitis D virus, or antigen of poliomyelitis virus. 7. Vaccine composition of Claim 1, wherein antigen compound is mixed with the aluminium-based adjuvant, having a zero point of charge of less than about 7.2. 8. Vaccine composition of Claim 7, wherein a compound, forming anions, are added to the aluminium-based adjuvant, whilst said compounds are phosphates and citates.
The present study was initiated to further increase the knowledge about the optimal dosing regimen and to thus optimize the efficacy and safety of MTX treatment for patients with moderate to severe psoriasis. In view of the described risk-benefit profile of MTX, an initial dose of at least 15 mg per week administered subcutaneously followed by 5 mg folic acid p.o. 24 hours after MTX application seems appropriate. Since 20 mg MTX per week has been proven to be beneficial in a considerable part of patients, who did not respond sufficiently to 15 mg MTX per week, in this study the dosing starts with a dose of 17.5 mg MTX per week, administered subcutaneously. At such a starting dose, it was expected to find the highest MTX efficacy possible, but with appropriate safety margins. If in a patient, a "50% reduction of Psoriasis Area Severity Index" PASI50 response is not achieved in week 8, the dose will be increased to 22.5 mg MTX per week. All dosages used in this study lay within the approved dosing range of MTX. The study will be conducted in a double-blind, placebo controlled manner. Placebo was chosen as control since only this comparator allows a reliable interpretation of safety and efficacy data.
PURPOSE:To obtain the subject agent useful for the prevention and treatment of diseases involving metabolic disturbance of purine such as hyperuricemia or gout, containing, as active ingredient, 1-(3-bromobenzo[b]furan-2-ylsulfonyl) hydantoin. CONSTITUTION:This uric acid-excretory agent contains, as active ingredient, at least one kind selected from 1-(3-bromobenzo[b]furan-2-ylsulfonyl)hydantoin of the formula, salts thereof, solvates thereof and solvates of the salts. This agent can be manufactured into pharmaceutical preparations such as tablets, capsules, powder, injections, suppositories, syrup, inhalants or ointments, its dose being 1-5000 (pref. 10-600) mg/day in terms of the compound of the formula. The compound of the formula. The compound of the formula, which has potent uric acid-excretory activity and is highly safe, is useful for the prevention and treatment of hyperuricemia as, a result of a complication of metabolic disturbance of saccharide with that of lipid, such as diabetes and hyperlipemia.
PURPOSE:To obtain a bathing agent composition, containing an oily ingredient, nonionic surfactant and cationic polymer and capable of moistening the skin after bathing and providing smoothness during and after the bathing with high humectant effects after the bathing. CONSTITUTION:The objective substance obtained by blending an oily ingredient (e.g., liquid paraffin) which is insoluble or sparingly soluble in water and a liquid or solid at ordinary temperature, a nonionic surfactant (e.g., glycerol ester of a fatty acid) and a water-soluble cationic polymer (e.g., cationic cellulose) in well-known raw materials for a bathing agent and preparing the bathing agent. In 100 pts.wt. bathing agent composition, are blended 0.5-50 pts.wt. oily ingredient, 5-100 pts.wt. nonionic surfactant and 0.01-20 pts.wt. cationic polymer. The bathing agent composition can be prepared in the form of powder, granule, tablet, liquid, etc.
PURPOSE: A composition for a sheet mask with excellent elasticity and a method for manufacturing the sheet mask using the same are provided to maintain high tensile strength. CONSTITUTION: A composition for a sheet mask contains 5-35 wt% of starch, 1-15 wt% of a water soluble natural polymer, 0.1-30 wt% of polyvalent alcohols, 0.1-5 wt% of a surfactant, and remaining amount of water. The starch is one or more selected from the group consisting of rice starch, sweet potato starch, tapioca starch, wheat starch, corn starch, mung bean starch, and soybean starch. A method for manufacturing the sheet mask comprises: a step of heating a mixture containing the starch and water at 70-90 deg. C; a step of dispersing the water soluble natural polymer in the polyvalent alcohols and preparing a dispersion solution; a step of adding the dispersion solution to the mixture; a step of additionally adding the surfactant at 60-80 deg. C; and a step of coating and drying at 40-60 deg. C.
A method of treating a hoof of an ungulate animal. The method comprises coating one or both of (i) at least a portion of a bottom surface of the hoof or (ii) at least a portion of a block surface with a curable polymer and allowing the polymer to cure for a period of time. The polymer is cured within 60 seconds or less of the coating and the cured polymer has a Shore D hardness of about 10 to about 50. The curable polymer is provided as a two component system. The first component is a reaction product of (a) comprises 4-4'-diphenylmethane - diisocyanate, castor oil, isocyanatopropyltriethoxysilane, and glycidoxypropyltrimethoxysilane, and wherein (b) comprises dicyclohexylmethane-4,4-diisocyanate, polyether polyol, 4,4'-diphenylmethane-diisocyanate (MDI), and triethoxy (3-isocyanatopropyle) silane. The second component comprises polyoxypropylene oxide ether polyol, diol (2000 MW), polyxoypropylene oxide ether polyol, triol (450 MW), tetrahydroxypropylethylendiamine, metaxylenediamine, and organobismuth catalyst.
Intervention: Fecal microbiota transplantation capsules containing extensively screened donor stool, prepared by OpenBiome, Medford, MA. 25 FMT capsules will be take on three consecutive days.
BACKGROUND: Direct oral anticoagulants (DOACs) are the mainstay of treatment for venous thromboembolism (VTE) and non-valvular atrial fibrillation (AF), with or without an underlying cancer. Patients with cancer have a 2-3-fold increase in risk for bleeding complications compared to non-cancer patients taking anticoagulant therapy, however the incidence of bleeding for urogenital and gynecological cancers on DOACs are uncertain.
AIMS: To assess the bleeding risk associated with the use of DOACs in patients with urogenital and/or gynecological cancers.
METHOD: We conducted a systematic review of randomized controlled trials (RCTs) and prospective cohort studies to address the safety of DOACs for VTE and AF when used in patients with urogenital and/or gynecological malignancy. The primary outcomes assessed were major and clinically relevant non-major (CRNMB) bleeding, with minor bleeding considered as a secondary outcome. MEDLINE, EMBASE and COCHRANE Central Registry of Controlled Trials were searched up to and including Oct 28, 2022. The study protocol was registered in PROSPERO (CRD42022370981). Studies were independently assessed for inclusion and data extracted in duplicate.
RESULT: Seven studies met our inclusion criteria (Fig. 1): 2 RCTs and 5 prospective cohort studies. A total of 676 patients treated with DOACs were included, 628 (92.8%) had VTE and 48 (7.1%) had AF. In patients with VTE treated with DOACs, the pooled major bleeding rate was 2.1%, 95% confidence intervals (CI) 0.9-3.3% (Fig. 2). Pooled estimates could not be determined for AF patients given small event and patient numbers.
CONCLUSION: Major bleeding rates in urogenital and/or gynecological cancer patients treated with DOACs are similar to that of the general cancer population.
With increasing life expectancy, more and more patients aged 65 or older will receive general anesthesia. Rapid recovery from anesthesia may reduce the incidence of many postoperative complications, such as postoperative delirium and cognitive dysfunction. Using inhalational anesthetics is the mainstay of general anesthesia. Since they pass readily into the brain, anesthetics are usually recognized as the important cause of postoperative cognitive dysfunction. Studies have shown that inhalation anesthesia may increase the risk of postoperative delirium in elderly patients compared to propofol, but such studies mostly focus on isoflurane and sevoflurane. Concentrations isoflurane caused aggregation of amyloid peptides in cell cultures, indicating that they brought cytotoxicity to the brain; sevoflurane also showed the same cytotoxic effect. However, some studies showed that inhalational anesthetics had a protective effect on postoperative cognitive function. Desflurane is currently known to be the least biotransformation inhaled anesthetic, whose blood-gas partition coefficient is only 0.42. Desflurane is increasingly used in elderly patients in clinical practice. However, it is not clear whether general anesthesia maintained mainly by desflurane reduces postoperative delirium and early cognitive dysfunction compared with sevoflurane-based general anesthesia
The invention belongs to the field of Chinese herbal medicines and particularly relates to a traditional Chinese composition capable of recuing blood pressure and blood lipid and a preparation method thereof. In the invention, fresh artemisia apiacea and radix rehmanniae are placed into a reaction kettle for reaction and are subjected to a concentrating process with peony roots in a rotary evaporator so that a sufficient action among the fresh artemisia apiacea, the radix rehmanniae and the peony roots is achieved. Finally a mixing process is carried out with other components. A blood pressure reducing function is greatly improved. In addition, the traditional Chinese medicine composition is quick in curative effects and enables a patient to feel a significant improvement just after 3-4 days. All of the components in the traditional Chinese medicine composition are Chinese herbal medicines so that the traditional Chinese medicine composition is free of toxic and side effects and can be widely applied in people in different stages. Raw materials of the traditional Chinese medicine composition are easy to obtain. The traditional Chinese medicine composition is easy to prepare, is low in production cost, is wide in effects, is high in safety and is significant in benefit.
Patients in this arm of the study will proceed with another programmed FET protocol which involves taking exogenous estrogen by mouth to stimulate the uterine lining to grow and develop. Once the lining has reached ≥ 7 mm and an endometrial pattern of type 1 or type 2, intramuscular progesterone in oil (50mg/ml daily) will be started at 8am on the morning that progesterone is initiated and continued per routine.
A platform for patient engagement and treatment compliance is disclosed. In an example, a system includes a home therapy machine configured to perform a renal failure therapy treatment. The system also includes a mobile communication device including an application having a calendar feature that identifies times/days in which the renal failure therapy treatment is scheduled to be performed. The application is configured to use the calendar feature to determine a time/day of a next scheduled renal failure therapy treatment. At a designated time before the next scheduled renal failure therapy treatment, the application causes a display interface of the personal mobile communication device to display a prompt for medical information. When the medical information is not received before the next scheduled renal failure therapy treatment, the application causes the home therapy machine to delay a start of the next scheduled renal failure therapy treatment.
Heart failure and cardiac remodeling are both characterized by mitochondrial dysfunction. Healthy mitochondria are required for adequate contractile activity and appropriate regulation of cell survival. In the mammalian heart, enhancement of the mitochondrial unfolded protein response (UPRmt) is cardioprotective under pressure overload conditions. We explored the UPRmt and the underlying regulatory mechanism in terms of hypertension-induced cardiac remodeling and the cardioprotective effect of metformin. Male spontaneously hypertensive rats and angiotensin II-treated neonatal rat cardiomyocytes were used to induce cardiac hypertrophy. The results showed that hypertension induced the formation of aberrant mitochondria, characterized by a reduced mtDNA/nDNA ratio and swelling, as well as lower levels of mitochondrial complexes I to V and inhibition of the expression of one protein subunit of each of complexes I to IV. Such changes eventually enlarged cardiomyocytes and increased cardiac fibrosis. Metformin treatment increased the mtDNA/nDNA ratio and regulated the UPRmt, as indicated by increased expression of activating transcription factor 5, Lon protease 1, and heat shock protein 60, and decreased expression of C/EBP homologous protein. Thus, metformin improved mitochondrial ultrastructure and function in spontaneously hypertensive rats. In vitro analyses revealed that metformin reduced the high levels of angiotensin II-induced mitochondrial reactive oxygen species in such animals and stimulated nuclear translocation of heat shock factor 1 (HSF1). Moreover, HSF1 small-interfering RNA reduced the metformin-mediated improvements in mitochondrial morphology and the UPRmt by suppressing hypertrophic signals and cardiomyocyte apoptosis. These results suggest that HSF1/UPRmt signaling contributes to the beneficial effects of metformin. Metformin-mediated targeting of mitochondrial protein homeostasis and modulation of HSF1 levels have potential therapeutic implications in terms of cardiac remodeling.
Each subject will be dispensed with two nasal spray device labelled as Device A and Device B containing FF or Placebo. Subject's on their own or with assistance from parent/guardian will administer FFNS 110 mcg per day, one intranasal spray from Device A, once daily into each nostril (27.5 mcg per spray) and another spray of placebo nasal spray from Device B, once daily into each nostril, in the morning for 4 Weeks.